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Colon cancer cells have previously been demonstrated to contain a subpopulation of CD133þ tumour cells that have the ability to
initiate tumour growth and are thus referred to as colon cancer-initiating cells or colon cancer stem cells (CSCs). As CD133 is
currently one of the best markers to characterise colon CSCs, we analysed CD133þ tumour cells in colorectal cancer specimens
using immunohistochemistry. We show that CD133 detection is specific and that the CD133 antigen is localised on the glandular-
luminal surface of colon cancer cells, whereas undifferentiated tumour cells at the front of invasion are CD133 . In addition,
CD133þ cells are characterised in situ by lack of CK20 expression, whereas they are positive for EpCAM. Moreover, we show that
CD133 expression in colorectal cancer is an independent prognostic marker that correlates with low survival in a stratified patient
collective. Our results indicate that in colorectal cancer, the CD133þ tumour cells can be detected by immunohistochemistry, which
facilitates their further characterisation in situ.
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The cancer stem cell (CSC) model is a current focus of cancer
research. According to this model, cancer cannot be viewed as
simple monoclonal expansions of functionally equal tumour cells.
Instead, despite their monoclonal origin, only a small minority of
tumour cells, the CSCs or ‘tumour-initiating cells’, have the ability
to maintain the malignant population (Reya et al, 2001; Brabletz
et al, 2005; Burkert et al, 2006).
Recent research findings suggest that among several other solid
malignancies, the CSC model also applies for colon carcinoma. In this
tumour, a CD133þ subpopulation of colon cancer cells was recently
demonstrated to be highly enriched in tumour-initiating colon CSCs
(Co-CSCs) that have the ability to self-renew and to recapitulate the
bulk tumour population (O’Brien et al, 2007; Ricci-Vitiani et al, 2007).
Furthermore, the CD133þ cells were able to retain tumorigenicity
in vitro as spheroid cultures and were shown to be resistant to
chemotherapeutic drugs, both characteristics of CSCs, whereas
CD133  cells had none of these features (Ricci-Vitiani et al, 2007;
Todaro et al, 2007). Thus, CD133 is currently one of the best markers
for the characterisation of Co-CSCs.
CD133 is a five-transmembrane domain molecule with a
molecular weight of 120kDa (Miraglia et al, 1997). It has been
shown to be located in apical plasma membrane protrusions of
embryonal epithelial structures as well as on the cultured colon
cancer cell line Caco-2 (Corbeil et al, 2000). It is implicated to
mark stem-like cells of various tissues and cancers (reviewed in
Mizrak et al, 2008). In colon cancer, CD133þ cells were shown to
be devoid of the intestinal epithelial differentiation marker
cytokeratin 20 (CK20), whereas they keep positivity for the
epithelial adhesion molecule EpCAM (Ricci-Vitiani et al, 2007).
Thus, in addition to their enrichment in Co-CSCs, CD133þ cells
show further distinct surface characteristics as compared with
CD133  tumour cells.
Although CD133 appears to be one of the most promising
markers to isolate and further characterise Co-CSCs, nothing is
known about the in situ localisation of CD133þ cells, their
immunohistochemical features, or their relevance for patient
outcome. Therefore, we investigated the expression of CD133 in
colorectal cancer specimens of a highly stratified patient collective.
We demonstrate that a subpopulation of tumour cells without the
expression of the differentiation marker CK20 displays strong
expression of CD133. This expression correlates significantly with
patient outcome. Our findings support the importance of CD133þ
tumour cells, and thus Co-CSCs for the malignant progression of
colorectal cancer.
MATERIALS AND METHODS
Clinical samples
Cases were selected from colorectal cancer specimens of patients
who underwent intentionally curative surgical resection between
1994 and 2004 at the Ludwig-Maximilians-Universita ¨tM u ¨nchen.
Follow up data were available from the Tumorregister Mu ¨nchen.
Only moderately differentiated colorectal adenocarcinomas (G2
according to World Health Organization) with T-categories T2 or
T3 and no nodal or distant metastasis at the time of diagnosis (N0,
M0) were considered. To reduce effects, directly related to surgery,
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sspecimens of patients who died within 6 months after surgical
resection were excluded. The final case collection included
colorectal cancer specimens of 77 patients; of whom, 21 (27%)
died of the diagnosed colorectal cancer within 5 years. The survival
data of 47 cases (61%) were censored, as case follow up was
discontinued or patients died of reasons other than colorectal
cancer. In the final case collection, only the T-category (T2 vs T3),
but neither age nor gender, was significantly associated with
patient outcome. Case characteristics are summarised in Supple-
mentary Table 1. The study complied with the guidelines of the
local ethics committee.
Immunohistochemistry
Immunohistochemical staining was carried out on 5mm sections of
formalin-fixed, paraffin-embedded tumour samples. Comparative
studies of CD133, CK20, and EpCAM were performed on adjacent
serial sections of 10 tumours with moderate-to-high CD133
expression. As primary antibodies for CD133 (AC133 antigen,
CD133/1) detection, we used anti-CD133 rabbit monoclonal
antibody (mAb) (1:100, clone C24B9, Cell Signaling, Danvers,
MA, USA), anti-CD133 mouse mAb (1:40, clone AC133, Miltenyi
Biotech, Bergisch Gladbach, Germany), and anti-CD133 goat
polyclonal antibody (1:200, Santa Cruz Biotechnology, Santa
Cruz, CA, USA), the first of which was used for analysis of the
patient samples. Further primary antibodies were anti-Ki67 mouse
mAb (1:50, clone MIB-1, Dako, Glostrup, Denmark), anti-EpCAM
mouse mAb (1:500, clone Ber-EP4, Dako), and anti-CK20 mouse
mAb (1:300, clone Ks20.8, Progen Biotechnik, Heidelberg,
Germany). For mouse and goat CD133 antibody staining, endo-
genous peroxidase was blocked using 7.5% hydrogen peroxide for
10min and primary antibody incubation was carried out at room
temperature for 60min. For detection, the Vectastain ABC-Kits
Elite Universal and Goat (Vector Laboratories, Burlingame, CA,
USA) were used, respectively, and slides were developed with DAB
(Dako). For all remaining antibodies, staining was performed on a
Ventana Benchmark autostainer with the XT ultraView DAB Kit
(Ventana Medical Systems, Illkirch, France). All slides were
counterstained with Hematoxylin (Vector Laboratories). To
exclude unspecific staining, isotype and system controls were
included for each of the used antibodies.
Evaluation of CD133 immunohistochemistry
CD133 immunostaining was evaluated on whole standard tissue
sections of colorectal adenocarcinomas. Five medium power
fields per section were viewed and tumours were given a
semi-quantitative score of 0, o50, and X50% CD133þ tumour
glands. Positivity of glands was defined as either membranous
staining or staining of shed cellular debris in the tumour glands.
The specimens were evaluated by two pathologists who had no
knowledge of prognosis and other clinicopathological variables.
Western blotting
Whole protein lysates of near confluent Caco-2 and DLD-1
cultured cell lines were used. Cell lines were obtained from the
American Type Culture Collection. A total of 45mg of protein were
used per lane. Primary antibodies were anti-b-actin mouse mAb
(1:10000; Sigma-Aldrich, Mu ¨nchen, Germany), and the anti-
CD133 antibodies that were used for immunohistochemistry (goat-
anti-CD133 at 1:200; mouse-anti-CD133 at 1:200; and rabbit-anti-
CD133 at 1:1000). Secondary antibodies were horseradish
peroxidase-coupled anti-rabbit, anti-mouse (both GE Healthcare
Europe, Freiburg, Germany), and anti-goat (Thermo Scientific,
Bonn, Germany). Enhanced chemoluminescence (Amersham
Biosciences Europe, Freiburg, Germany) was used for detection,
according to the manufacturer’s protocol.
Statistical analysis
Cross-tabulations were calculated using Fisher’s exact test. The
Kaplan–Meier analysis was used to estimate cancer-specific
survival, and the groups were compared with the log-rank test.
Multivariate analysis was based on the Cox regression model.
Statistical procedures were performed using SPSS version 15.0
(SPSS Inc., Chicago, IL, USA). Po0.05 was considered statistically
significant.
RESULTS
CD133 is specifically detected in colorectal cancer
specimens by immunohistochemistry
Before colorectal cancer specimens were immunohistochemically
evaluated for CD133 expression, specificity of the antibodies had to
be determined. Therefore, we compared serial tumour sections
stained with three different antibodies raised against CD133. Those
included the antibody that was previously used for the isolation of
CD133þ cells from tumour cell suspensions (O’Brien et al, 2007;
Ricci-Vitiani et al, 2007). All three antibodies revealed comparable
ABCD
Figure 1 CD133 expression is found on the glandular-luminal surface of epithelial tumour cells. Three different antibodies were compared on serial
tumour sections: (A) monoclonal anti-CD133 (Cell Signalling), (B) monoclonal anti-CD133 (Miltenyi Biotech), and (C) polyclonal anti-CD133 (Santa Cruz
Biotechnology). All three antibodies showed comparable staining patterns. Arrowheads indicate positive (black) and negative (white) staining; original
magnification,  200. (D) High magnification of positively stained tumour cells; original magnification,  630.
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(Figure 1A–C). In addition, Western analysis of cell lysates from
the CD133þ colon cancer cell line Caco-2 (Corbeil et al, 2000) and
the CD133  cell line DLD-1 (unpublished results) showed specific
protein detection with all three used antibodies (Figure 2).
Therefore, the immunohistochemical in situ approach specifically
detects the CD133 antigen.
The CD133 antigen is located at the glandular-luminal
surface of colorectal cancer cells
The CD133 antigen has previously been shown to be located in
apical plasma membrane protrusions of embryonic epithelial cells
as well as on the apical cell surface of the cultured colon cancer cell
line Caco-2 (Corbeil et al, 2000). Comparably, we observed
staining of CD133 on the luminal cell surface of colorectal cancer
glands (Figure 1D). Only tumour cells with direct contact to these
luminal surfaces were CD133þ. Usually, several CD133þ tumour
cells were grouped together with some glands being completely
positive. In addition, most CD133-expressing tumours showed
shedding of CD133þ cellular debris into the glandular lumina
(Figure 3A). In tumour glands with CD133þ tumour cells,
intraglandular cellular debris was always, at least partially,
CD133þ. When intraglandular debris was CD133 , the tumour
cells were always CD133 . CD133 expression tended to be
pronounced close to the invasive margin of the tumours
(Figure 3B). However, small groups of infiltrating tumour cells at
the front of tumour invasion, referred to as tumour ‘buds’ (Hase
et al, 1993), showing no lumen formation, were generally CD133 
(Figure 3B). Taken together, CD133 expression in colorectal cancer
is polar, confined to the apical luminal surface of colorectal cancer
cells with glandular differentiation, which is in accordance with the
previous results. In addition, CD133 staining of intraglandular
cellular debris mirrors CD133 expression of the surrounding
tumour cells.
CD133þ colorectal cancer cells lack CK20 expression
while they are EpCAMþ
Previous studies using cell suspensions of colon cancer specimens
demonstrated that CD133þ cells were CK20 , whereas both
CD133þ as well as CD133  cells expressed the epithelial cell
adhesion molecule EpCAM (Ricci-Vitiani et al, 2007). Thus, we
expected to find comparable results on colorectal cancer cells
in situ. Therefore, we used serial tumour sections and stained for
CD133, CK20, and EpCAM. Expectedly, areas with many CD133þ
cells showed none to very low CK20 expression, whereas areas
expressing high amounts of CK20 were generally CD133 
(Figure 4). Furthermore, the tumours contained subpopulations
Rabbit anti-CD133 Mouse anti-CD133 Goat anti-CD133
M D1 C2 M D1 C2 M D1 C2
120 kDa
-Actin
Figure 2 Specificity of CD133 detection. Protein lysates of the CD133 
DLD-1 (D1) and the CD133þ Caco-2 (C2) colon cancer cell lines were
blotted and stained with the three anti-CD133 antibodies used for
immunohistochemistry. All three antibodies strongly detected the CD133
antigen in Caco-2, displayed at 120kDa, whereas DLD-1 showed no
staining. Unspecific bands that were observed were considered to be
negligibly weak. b-Actin was used as control. Upper panel images show full-
length Western blots merged with their molecular weight markers (M).
AB
Figure 3 (A) CD133 staining of shed intraglandular cellular debris
mirrors CD133 expression of the surrounding tumour cells. Arrows
indicate a CD133  tumour gland filled with CD133  debris. Arrowheads
indicate a CD133þ gland with CD133þ cellular debris and apical staining
of the tumour cells. Tumour glands were considered as CD133þ if either
apical CD133 staining of the tumour cells or CD133þ cellular debris or
both were present. (B) CD133 only marks tumour cells that are gland
forming. Undifferentiated tumour ‘buds’ at the front of tumour invasion are
CD133  (arrowheads). Original magnification,  200 (A),  400 (B).
ABC
Figure 4 CD133 and CK20 expressions are mutually exclusive. Serial sections stained for CD133 (A), CK20 (B), and EpCAM (C) demonstrate that
CD133þ cells are negative for CK20, whereas CD133þ and CD133  cells express the EpCAM antigen. Original magnification,  200.
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detected in comparable amounts in both CD133þ and CD133 
areas (Figure 4). These patterns were found in 8 out of 10 tumour
cases, whereas 2 cases were not evaluable as they showed widely
distributed presence of CD133, which did not allow a reliable
correlation with CK20 staining (data not shown). The expression
pattern of our in situ results are thus in line with previously
published data about the CD133þ cell phenotype.
CD133 expression in colorectal cancer strongly correlates
with patient survival
CD133 expression was scored on the basis of CD133þ tumour
glands. Tumours showing more than 50% positive glands (either
apical staining or staining of intraglandular cellular debris) were
considered as CD133-high, whereas those with less than 50%
stained glands were CD133-low (Figure 5). Applying this criterion,
26% of the tumours were CD133-high and 74% were CD133-low.
When comparing the CD133 status with clinicopathological
variables, no correlation with age, gender, or T-category of the
tumour was observed (Table 1). Next, we examined the correlation
of CD133 expression with patient outcome employing the Kaplan–
Meier analysis. Patients with CD133-high tumours were associated
with a significant worse 5- and 10-year survival than those with
CD133-low tumours (P¼0.002; Figure 6). Applying multivariate
Cox regression, we found that the CD133-high expression
represented an independent relative risk of 2.45 compared with
the CD133-low group (P¼0.018; Table 2). While age and gender
were not significantly associated with outcome, the only other
parameter that was marginally significant in multivariate analysis
was the T-category with T3 having a relative risk of 2.51 compared
with T2 (P¼0.073).
DISCUSSION
In this study, we investigated the expression of CD133 in colorectal
cancer using an immunohistochemical approach. As the localisa-
tion of CD133þ colorectal cancer cells has not yet been
characterised in situ, we had to verify that our approach truly
detects the CD133 antigen. Thus, we used three different
ABC
Figure 5 Scoring of CD133 expression in colorectal cancer. Tumours that showed no staining (A) and tumours with less than 50% positively stained
glands (B) were considered as CD133-low; tumours with more than 50% positively stained glands as CD133-high (C). Original magnification,  200.
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Figure 6 CD133 expression correlates with low survival. The Kaplan–
Meier plot of colorectal cancer specimens (n¼77) demonstrates significant
(log-rank test) lower survival with CD133-high expression.
Table 1 CD133 expression does not correlate with age, gender, or
T-category of the investigated colorectal cancer cases
Variable CD133 low CD133 high P-value
Gender
Male 36 10 0.43
Female 21 10
Age, years
p69 31 11 1.0
X70 26 9
T-category
T2 24 4 0.11
T3 33 16
Table 2 Multivariate survival analysis
Variable Relative risk (95% confidence interval) P-value
CD133
Low 1.00
High 2.45 (1.18–5.13) 0.018
Gender
Male 1.00
Female 0.88 (0.42–1.84) 0.74
Age, years
p69 1.00
X70 1.28 (0.61–2.65) 0.52
T-category
T2 1.00
T3 2.51 (0.92–6.85) 0.073
CD133 expression in colorectal carcinoma is an independent marker for low patient
survival.
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comparable staining patterns on serial tumour sections. In
addition, we demonstrate that CD133þ cell groups were CK20 
and EpCAMþ, which is in accordance with previous studies that
characterised the phenotype of CD133þ colon cancer cells using
tumour cell suspensions (Dalerba et al, 2007; Ricci-Vitiani et al,
2007). Moreover, we found the CD133 antigen at the luminal
surface of epithelial tumour glands with shedding into the lumina,
while no other staining pattern was observed. This complies with
previous results of CD133 detection in embryonal tissue and on the
apical surface of the cultured colon cancer cell line Caco-2 (Corbeil
et al, 2000). Taken together, the specificity of our results is
supported by previous studies in colorectal cancer. However,
staining results, which differ from the positivity of the luminal
surface in colorectal cancer, have recently been reported in
pancreatic cancer, where a cytoplasmic expression of CD133 was
shown (Hermann et al, 2007; Maeda et al, 2008). Such organ-
specific patterns of CD133 expression still have to be clarified in
further studies.
The CD133þ subpopulation of colon cancer cells was recently
demonstrated to be highly enriched in tumour-initiating Co-CSCs,
whereas in contrast, CD133  tumour cells did not have tumour-
initiating capabilities (O’Brien et al, 2007; Ricci-Vitiani et al, 2007).
CD133 is therefore currently one of the best markers for the
detection of Co-CSCs. As Co-CSCs are hypothesised to be central
for tumour relapse and progression (Brabletz et al, 2005; Ricci-
Vitiani et al, 2008), we investigated CD133 expression in a
collection of colorectal adenocarcinomas that was highly stratified
towards patient outcome. Expectedly, CD133 expression was
strongly associated with patient survival and proofed to be an
independent prognostic marker.
Another prognostic marker that has previously been described
for colon cancer is tumour ‘budding’; that is, small clusters of
undifferentiated cells ahead of the invasive front (Hase et al, 1993;
Ueno et al, 2002). We therefore expected to find CD133þ budding
tumour cells in colorectal cancer. Although CD133 expression was
pronounced in tumour glands close to the invasive margin, CD133
expression was restricted to glandular differentiated cells and
budding tumour cells were generally CD133 . As both makers
correlate with patient survival, it might be speculated whether
budding tumour cells contain a population of Co-CSCs that are not
characterised by CD133 expression.
Although CD133 is currently one of the best markers to
characterise Co-CSCs, by far not every CD133þ cell is a
Co-CSC. It was estimated that 1 in 262 CD133þ colon cancer
cells actually has tumour-initiating capabilities (O’Brien et al,
2007). We demonstrate that in some tumours, several cells or even
whole tumour glands are CD133þ, whereas the actual Co-CSCs
among them cannot be further confined using this marker. Thus,
although the immunostaining for CD133 might correlate with the
amount of Co-CSCs and can be used to estimate their impact on
prognosis, CD133 appears to be inappropriate for the morpholo-
gical characterisation of single Co-CSCs and their niche.
Taken together, we provide further evidence that the CD133þ
tumour cell population in colorectal cancer is specifically, although
not exclusively, important for colon cancer progression, and we
present an approach that can be applied for further characterisa-
tion of these cells in situ.
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